NASDAQ$EWTX
Edgewise Therapeutics Inc · Q4 2022 earnings
Q4 2022 earnings · · Investor relations
Briefing
Edgewise Therapeutics reported fourth quarter and full year 2022 financial results and recent business highlights.
Edgewise Therapeutics reported a net loss of $19.4 million, or $0.31 per share, for the fourth quarter of 2022. The company's cash, cash equivalents and marketable securities were $352 million as of December 31, 2022. They are advancing EDG-5506 clinical trials and EDG-7500 IND-enabling studies.
- Advanced Phase 2 trials of EDG-5506 in Becker muscular dystrophy (BMD, CANYON) and Duchenne muscular dystrophy (DMD, LYNX).
- Initiated Phase 2 exercise challenge trial of EDG-5506 in Limb girdle muscular dystrophy 2i (LGMD2I), BMD and McArdle’s Disease (DUNE).
- Initiated IND-enabling studies of EDG-7500, a novel sarcomere modulator for hypertrophic cardiomyopathy (HCM); Phase 1 start expected in 2H2023.
- Cash, cash equivalents and marketable securities of $352 million as of December 31, 2022.
Headline financials
Revenue & EPS history
Edgewise Therapeutics · Revenue · Quarterly
$0
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2022
-0.2%
Avg return
Earnings day
+0.7%
Avg return
5 days after
-4.0%
Avg return
30 days after
40%
8 / 20 earnings
Positive
+16.0%
Q2 2022
Best reaction
-12.3%
Q1 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | -1.7% | -4.3% | +2.4% | |
| Q3 2025 | -1.7% | +23.7% | +35.8% | |
| Q2 2025 | -4.1% | -0.9% | +15.2% | |
| Q1 2025 | +2.4% | +1.0% | +5.8% | |
| Q4 2024 | -2.4% | +7.0% | -40.7% | |
| Q3 2024 | -0.7% | -3.9% | -11.0% | |
| Q1 2024 | -12.3% | -16.5% | -15.5% | |
| Q4 2023 | -1.3% | -3.7% | -7.1% | |
| Q3 2023 | -10.7% | +5.5% | +13.0% | |
| Q2 2023 | +3.4% | +12.5% | -3.4% | |
| Q1 2023 | -6.5% | -5.5% | -2.8% | |
| Q4 2022 | -3.0% | -2.8% | -30.3% | |
| Q3 2022 | +1.8% | +2.1% | -5.7% | |
| Q2 2022 | +16.0% | +6.8% | +17.1% | |
| Q1 2022 | +1.6% | -0.8% | -18.9% | |
| Q4 2021 | +13.0% | -2.5% | -19.3% | |
| Q3 2021 | -1.8% | -3.4% | -3.1% | |
| Q2 2021 | -5.6% | -10.6% | -7.9% | |
| Q1 2021 | +5.2% | +4.7% | -1.6% | |
| Q4 2020 | +5.2% | +4.7% | -1.6% | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro